Alpha-1-antitrypsin - CSL Behring

Drug Profile

Alpha-1-antitrypsin - CSL Behring

Alternative Names: AAT - CSL Behring; Alpha-1 proteinase inhibitor - CSL Behring; Alpha-antitrypsin - CSL Behring; API; API Inhale; Respreeza; Zemaira

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator CSL Behring
  • Developer CSL Behring; Nektar Therapeutics
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency

Most Recent Events

  • 02 Dec 2016 Launched for Alpha 1-antitrypsin deficiency in Europe (IV)
  • 21 Sep 2016 Registered for Alpha 1-antitrypsin deficiency in Canada (IV)
  • 03 Sep 2016 Efficacy data from the phase III RAPID trial in Alpha 1-antitrypsin deficiency presented at 26th Annual Congress of the European Respiratory Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top